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geal carcinoma (NPC) and Hodgkin’s disease (HD). We have
shown in the past that LMP1- and LMP2-speciﬁc T-cells can be
activated from EBV-seropositive individuals with adenoviral vec-
tors encoding either an inactive form of LMP1 (dLMP1) or LMP2.
The aim of this study was to construct and characterize an adeno-
viral vector containing dLMP1 and LMP2 (Ad_dLMP1-I-LMP2)
for the generation of LMP1- and LMP2-speciﬁc T cells. Meth-
ods: To evaluate the activity of Ad-dLMP1-I-LMP2 to reactivate
LMP1- and LMP2-speciﬁc CTL, we took advantage of the tro-
pism of Ad5F35 adenoviral vectors, which preferentially transduce
monocytes after incubation of peripheral blood mononuclear cells
(PBMC). Transduced monocytes expressed LMP1 and LMP2, and
reactivated LMP1- and LMP2-speciﬁc T cells, that could be ex-
panded further with autologous LCL transduced with Ad-dLMP1-
I-LMP2. The presence of LMP1- and LMP2-speciﬁc CTL was
determined by tetramer analysis, IFN- ELISPOT assays and
cytotoxicity assays. Results: Stimulation of PBMC with Ad-
dLMP1-I-LMP2 transduced monocytes from 10 HLA-A2, EBV-
seropositive donors resulted in an at least 30 to 100 fold expansion
of LMP1- or LMP2-speciﬁc T-cells as judged by the presence of
HLA-A2 restricted, tetramer positive T-cells. LMP2-speciﬁc re-
sponses were detected in all donors where as LMP1-speciﬁc re-
sponses were found in 7/10 donors. The presence of LMP1- and
LMP2-speciﬁc T-cells was conﬁrmed in a subset of donors with
IFN- ELISPOT assays. In addition, generated LMP1- and
LMP2-CTL killed autologous ﬁbroblasts expressing LMP1 and
LMP2, as well as LCL. Conclusion: The constructed adenoviral
vector, Ad-dLMP1-I-LMP2, is a promising candidate for the ex
vivo generation of LMP1- and LMP2-speciﬁc CTL and may also
be used as a vaccine for the in vivo boosting of adoptively trans-
ferred T cells. Targeting the subdominant LMP antigens ex-
pressed in NPC and HD may improve the efﬁcacy of adoptive
immunotherapy approaches.
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We studied 6548 recipients of allogeneic HCTs performed be-
tween 1978 and 1997 to determine long-term rates of overall
survival, disease-free survival and relapse. As of December 2002,
2710 of the 6548 had survived for 	5 yr, 1926 for 	7 yr, 1044 for
	10 yr, 212 for 	15 yr and 7 for 	20 yr. 2234 patients were alive
and in continuing remission 5 or more years post-HCT. Of these,
the median age at HCT was 34 yrs, 60% had received TBI as part
of their conditioning; 67% had received cyclosporine and metho-
trexate for graft-versus-host disease (GVHD) prophylaxis. Among
patients alive and in remission 5 yrs after HCT, the cumulative
incidences of subsequent relapse at 15 yrs post-HCT were 17%,
15%, 12% and 7% for recipients of sibling transplants in ﬁrst
chronic phase (CP), recipients of sibling transplants not in ﬁrst CP,
recipients of alternative donor transplants in ﬁrst CP and recipients
of alternative donor transplants not in ﬁrst CP respectively. The
latest relapse occurred at 16 yr post HCT. Corresponding survival
rates at 15 years in the patients were 85%, 83%, 80% and 75%. 174
of the 2234 patients surviving in remission at 5 years post HCT
subsequently died; the causes of death were CML (2% of 5 year
survivors), GVHD (1%), second cancer (1%), infection (1.4%),
organ failure (1%) and other (1%). We conclude that remissions
after allogeneic HCT are generally durable. However, after a
high-risk period early post-HCT, there is a low but constant risk of
relapse. Rescue strategies in patients with late relapse may include
donor cell infusions or imatinib, though few data exist regarding
the efﬁcacy of these approaches in this patient group.
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DETECTION OF BCR-ABL EXPRESSION IN HUMAN CML MODEL USING
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Introduction of imatinib marked a pivot point in history of
treatment of chronic myelogenic leukemia (CML). Speciﬁc inhi-
bition of bcr-abl kinase interrupts pathologic signal transduction
pathway, terminating tumor growth. To facilitate identiﬁcation of
the patients eligible for imatinib therapy we developed a non-
invasive in vivo imaging technique enabling detection of abl-kinase
expression by PET. A speciﬁc abl-protein kinase inhibitor (PKI)
DV was developed to be radiolabeled. K562—human CML cell
line (overexpressing bcr-abl) and A431—human GBM cell line (low
for abl) were chosen as models. Levels of abl expression were
conﬁrmed by Western blot. In vitro radiotracer accumulation
studies were done with [131I]DV. For in vitro studies subcutaneous
xenograft tumor models were created in contralateral shoulders of
nude rnu/rnu rats. Upon tumor size of 1 cm3, [124I]DL was injected
IV to the rats for 2 sets of scans: 40 Ci for microPET and 200 Ci
for clinical PET-Advance. Acquisition was performed in dynamic
10 min frames for 60 min on microPET and 90 min on PET-
Advance. After image reconstruction ROIs were analyzed for ra-
diotracer dynamics. MicroPET imaging showed accumulation of
[124I]DV in K562 tumor with low background signal in the rest of
the animal. Maximal accumulation in early frames appeared to be
in projection of liver. Imaging on clinical PET-Advance scanner
demonstrated speciﬁc accumulation of [124I]DV radiotracer in hu-
man CML K562 tumor model over 90 min of imaging session. No
accumulation in abl-negative A431 was detected. There was con-
current monophasic clearance of the radiotracer form the circula-
tion. Initial high concentration of the radiotracer in the liver was
gradually clearing out with concomitant increase of bowel signal
demonstrating hepato-biliary clearance. Non-invasive assessment
of bcr-abl expression is feasible by PET-visualization using
[124I]DV, radiolabeled abl-PKI. Detection of bcr-abl expression in
vivo will not only assist identifying treatment target for imatinib
therapy in patients, it might assist monitoring the course of CML
therapy with imatinib. This method can also be used as a screening
option for selection of patients with abl-overexpression in other
types of tumors.
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Disease relapse is a frequent cause of treatment failure in patients
undergoing non-myeloablative allogeneic stem cell transplantation
(NST) for advanced myelodysplastic syndrome (MDS) and acute
myeloid leukemia (AML). GVAX, a cancer vaccine composed of
leukemia cells modiﬁed by adenoviral vector mediated gene trans-
fer to secrete GM-CSF, has demonstrated activity in MDS and
AML. We initiated a trial investigating the feasibility and safety of
administering GVAX after allogeneic NST. Patients with MDS-
RAEB or AML not in remission with a donor matched at HLA-
A,B, and DRB1 were eligible. Leukemia blasts were collected for
GVAX generation prior to conditioning. The preparative regimen
consisted of ﬂudarabine 30 mg/m2/d IV days 6 to 3, and
Busulfex 0.8 mg/kg IV q12h  8 doses from days 6 to 3. All
patients received G-CSF mobilized PBSC. GVHD prophylaxis
included tacrolimus starting day3, and methotrexate 5 mg/m2 IV
days 1, 3, 6, 11. GM-CSF (Leukine) 250 mg/m2 SC QD was given
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